Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 1
1999 5
2000 1
2001 5
2002 6
2003 4
2004 5
2006 3
2008 5
2009 9
2010 9
2011 14
2012 12
2013 9
2014 9
2015 12
2016 12
2017 25
2018 10
2019 11
2020 13
2021 11
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Results by year

Filters applied: . Clear all
Page 1
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. Conroy T, et al. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923. N Engl J Med. 2011. PMID: 21561347 Free article. Clinical Trial.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. N Engl J Med. 2014. PMID: 25014687 Free article. Clinical Trial.
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.
Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Baudin E, et al. Among authors: lombard bohas c. Ann Oncol. 2021 Apr;32(4):439-451. doi: 10.1016/j.annonc.2021.01.003. Epub 2021 Jan 19. Ann Oncol. 2021. PMID: 33482246 Free article. No abstract available.
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Raymond E, et al. Among authors: lombard bohas c. N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. N Engl J Med. 2011. PMID: 21306237 Free article. Clinical Trial.
[Metastatic bronchial carcinoid tumors].
Bouledrak K, Walter T, Souquet PJ, Lombard-Bohas C. Bouledrak K, et al. Among authors: lombard bohas c. Rev Pneumol Clin. 2016 Feb;72(1):41-8. doi: 10.1016/j.pneumo.2015.12.002. Epub 2016 Jan 30. Rev Pneumol Clin. 2016. PMID: 26831129 Review. French.
Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Delhomme C, Walter T, Arangalage D, Suc G, Hentic O, Cachier A, Alkhoder S, François L, Lombard-Bohas C, Iung B, Ruszniewski P, de Mestier L. Delhomme C, et al. Among authors: lombard bohas c. J Neuroendocrinol. 2023 Apr;35(4):e13262. doi: 10.1111/jne.13262. Epub 2023 Apr 2. J Neuroendocrinol. 2023. PMID: 37005217 Review.
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T. Lepage C, et al. Among authors: lombard bohas c. Eur J Cancer. 2022 Nov;175:31-40. doi: 10.1016/j.ejca.2022.07.033. Epub 2022 Sep 7. Eur J Cancer. 2022. PMID: 36087395 Free article. Clinical Trial.
[Angiogenesis and endocrine tumors].
Dumortier J, Ratineau C, Roche C, Lombard-Bohas C, Chayvialle JA, Scoazec JY. Dumortier J, et al. Among authors: lombard bohas c. Bull Cancer. 1999 Feb;86(2):148-53. Bull Cancer. 1999. PMID: 10066945 Free article. Review. French.
New treatment strategies in advanced neuroendocrine tumours.
Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G. Walter T, et al. Among authors: lombard bohas c. Dig Liver Dis. 2012 Feb;44(2):95-105. doi: 10.1016/j.dld.2011.08.022. Epub 2011 Oct 7. Dig Liver Dis. 2012. PMID: 21983252 Review.
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C. Walter T, et al. Among authors: lombard bohas c. Lancet Oncol. 2023 Mar;24(3):297-306. doi: 10.1016/S1470-2045(23)00001-3. Epub 2023 Feb 2. Lancet Oncol. 2023. PMID: 36739879 Clinical Trial.
175 results